Incretins: their physiology and application in the treatment of diabetes mellitus

The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · see citing works

The Physiology of Glucagon-like Peptide 1

Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works

The biology of incretin hormones

Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · see citing works

A role for glucagon-like peptide-1 in the central regulation of feeding

Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · see citing works

U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease

U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923 · see citing works

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works

Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40

Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., et al. (2003) · Nature · doi:10.1038/nature01478 · Cited by 1,538 · see citing works

Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120

Hirasawa, A., Tsumaya, K., Awaji, T., Katsuma, S., Adachi, T., Yamada, M., Sugimoto, Y., Miyazaki, S., & Tsujimoto, G. (2004) · Nature Medicine · doi:10.1038/nm1168 · Cited by 1,535 · see citing works

Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · see citing works

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · see citing works

Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides

Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,273 · see citing works

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.

Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209 · see citing works

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161 · see citing works

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · see citing works

The Glucagon-Like Peptides

Kieffer, T. J., & Habener, J. F. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,056 · see citing works

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · see citing works

Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV

Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955 · see citing works

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · see citing works

Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916 · see citing works

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.

Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · see citing works

Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · see citing works

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

Deacon, C. F., Nauck, M. A., Toft-Nielsen, M.-B., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diabetes.44.9.1126 · Cited by 878 · see citing works

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 876 · see citing works

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · see citing works

Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus

Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · see citing works

STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. ¹

Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860 · see citing works

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · see citing works

Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes: A Randomized Trial

Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795 · see citing works

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · see citing works

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · see citing works

New Interpretation of Oral Glucose Tolerance

Mcintyre, N., Holdsworth, C. D., & Turner, D. S. (1964) · The Lancet · doi:10.1016/s0140-6736(64)90011-x · Cited by 738 · see citing works

Glucose Sensing in L Cells: A Primary Cell Study

Reimann, F., Habib, A. M., Tolhurst, G., Parker, H. E., Rogers, G. J., & Gribble, F. M. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.11.002 · Cited by 733 · see citing works

Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

Åhrén, B., Landin‐Olsson, M., Jansson, P., Svensson, M. K. E., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710 · see citing works

Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration

Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 705 · see citing works

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease

Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · see citing works

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation

Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 4× · see citing works

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

Bose, A. K., Mocanu, M., Carr, R. D., Brand, C. L., & Yellon, D. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 642 · see citing works

Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers

Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605 · see citing works

Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats

Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597 · see citing works

Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis

Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589 · see citing works

<i>Gpr40</i> Is Expressed in Enteroendocrine Cells and Mediates Free Fatty Acid Stimulation of Incretin Secretion

Edfalk, S., Steneberg, P., & Edlund, H. (2008) · Diabetes · doi:10.2337/db08-0307 · Cited by 587 · see citing works

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.

Stoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner‐Weir, S., Habener, J. F., & Egan, J. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576 · see citing works

Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy

Nikolaidis, L., Elahi, D., Hentosz, T., Doverspike, A., Huerbin, R., Zourelias, L., Stolarski, C. J., Shen, Y.-T., & Shannon, R. (2004) · Circulation · doi:10.1161/01.cir.0000139339.85840.dd · Cited by 546 · see citing works

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26

Marguet, D., Baggio, L. L., Kobayashi, T., Bernard, A., Pierres, M., Nielsen, P. F., Ribel, U., Watanabe, T., Drucker, D. J., & Wagtmann, N. R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120069197 · Cited by 538 · see citing works

Cell and Molecular Biology of the Incretin Hormones Glucagon-Like Peptide-I and Glucose-Dependent Insulin Releasing Polypeptide

Fehmann, H. C., Göke, R., & Göke, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 527 · see citing works

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses

Herman, G. A., STEVENS, C., Vandyck, K., Bergman, A. J., Yi, B., DESMET, M., Snyder, K., Hilliard, D., Tanen, M. R. L., & Tanaka, W. K. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 521 · see citing works

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men

Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · see citing works

Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509 · see citing works

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502 · see citing works

Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes

Lankas, G. R., Leiting, B., Roy, R. S., Eiermann, G. J., Beconi, M. G., Biftu, T., Chan, C., Edmondson, S. D., Feeney, W. P., He, H., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2988 · Cited by 494 · see citing works

Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes

Ahrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487 · see citing works

cAMP-GEFII is a direct target of cAMP in regulated exocytosis

Ozaki, N., Shibasaki, T., Kashima, Y., Miki, T., Takahashi, K., Ueno, H., Sunaga, Y., Yano, H., Matsuura, Y., Iwanaga, T., et al. (2000) · Nature Cell Biology · doi:10.1038/35041046 · Cited by 481 · see citing works

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J. P., Verhoeven, R., Bugáňová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 467 · see citing works

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus: A Population-Based Matched Case-Control Study

Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467 · see citing works

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

Edwards, C. M. B., Stanley, S. A., Davis, R. P., Brynes, A. E., Frost, G. S., Seal, L., Ghatei, M. A., & Bloom, S. R. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.1.e155 · Cited by 464 · see citing works

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457 · see citing works

Thyroid Cancer Incidence Patterns in the United States by Histologic Type, 1992–2006

Aschebrook‐Kilfoy, B., Ward, M. H., Sabra, M. M., & Devesa, S. S. (2010) · Thyroid · doi:10.1089/thy.2010.0021 · Cited by 454 · see citing works

Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice

Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · see citing works

Incretins, insulin secretion and Type 2 diabetes mellitus

Vilsbøll, T., & Holst, J. J. (2004) · Diabetologia · doi:10.1007/s00125-004-1342-6 · Cited by 447 · see citing works

Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects

Vilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444 · see citing works

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

Young, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1026 · Cited by 440 · see citing works

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus

Kolterman, O., Kim, D. D. H., Shen, L. Z., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434 · see citing works

Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms

I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432 · see citing works

One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes

Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427 · see citing works

Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

Kennedy, L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79145-5 · Cited by 425 · see citing works

Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes

Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421 · see citing works

Aace Comprehensive Diabetes Management Algorithm 2013

Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garvey, W. T., Grunberger, G., et al. (2013) · Endocrine Practice · doi:10.4158/endp.19.2.a38267720403k242 · Cited by 393 · see citing works

Epac: A New cAMP-Binding Protein in Support of Glucagon-Like Peptide-1 Receptor-Mediated Signal Transduction in the Pancreatic β-Cell

Holz, G. G. (2004) · Diabetes · doi:10.2337/diabetes.53.1.5 · Cited by 392 · see citing works

Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP

Theodorakis, M. J., Carlson, O. D., Michopoulos, S., Doyle, M. E., Juhaszova, M., Petraki, K., & Egan, J. M. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00326.2004 · Cited by 391 · see citing works

A Recombinant Human Glucagon-Like Peptide (GLP)-1–Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor–Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis

Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 388 · see citing works

A Role for Intestinal Endocrine Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Peptide Release

Chu, Z., Carroll, C., Alfonso, J., Gutierrez, V., He, H., Lucman, A., Pedraza, M., Mondala, H., Gao, H., Bagnol, D., et al. (2008) · Endocrinology · doi:10.1210/en.2007-0966 · Cited by 387 · see citing works

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

Fonseca, V. A., Schweizer, A., Albrecht, D., Baron, M. A., Chang, I.-Y., & Dejager, S. (2007) · Diabetologia · doi:10.1007/s00125-007-0633-0 · Cited by 370 · see citing works

Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes

Drucker, D. J. (2007) · Diabetes Care · doi:10.2337/dc07-0228 · Cited by 367 · see citing works

Glucagon-Like Peptide-1 and Exendin-4 Stimulate β-Cell Neogenesis in Streptozotocin-Treated Newborn Rats Resulting in Persistently Improved Glucose Homeostasis at Adult Age

Tourrel‐Cuzin, C., Bailbé, D., Meile, M.-J., Kergoat, M., & Portha, B. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1562 · Cited by 361 · see citing works

Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes

Fineman, M. S., Bicsak, T. A., Shen, L. Z., Taylor, K., Gaines, E., Varns, A., Kim, D. S., & Baron, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2370 · Cited by 353 · see citing works

Reduced Incretin Effect in Type 2 Diabetes

Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349 · see citing works

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

Wang, Q.-H., & Brubaker, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0828-3 · Cited by 348 · see citing works

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

Conarello, S., Li, Z., Ronan, J., Roy, R. S., Zhu, L., Jiang, G., Liu, F., Woods, J. W., Zycband, E., Moller, D. E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0631828100 · Cited by 346 · see citing works

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.

Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · see citing works

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1137 · Cited by 339 · see citing works

Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells

Parker, H. E., Habib, A. M., Rogers, G. J., Gribble, F. M., & Reimann, F. (2009) · Diabetologia · doi:10.1007/s00125-008-1202-x · Cited by 324 · see citing works

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

Deacon, C. F., Hughes, T. E., & Holst, J. J. (1998) · Diabetes · doi:10.2337/diabetes.47.5.764 · Cited by 321 · see citing works

Improved Meal-Related β-Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin-Treated Patients With Type 2 Diabetes Over 1Year

Åhrén, B., Pacini, G., Foley, J. E., & Schweizer, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1936 · Cited by 309 · see citing works

Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors

Hansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309 · see citing works

Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats

Szayna, M., Doyle, M. E., Betkey, J. A., Holloway, H. W., Spencer, R. G. S., Greig, N. H., & Egan, J. M. (2000) · Endocrinology · doi:10.1210/endo.141.6.7490 · Cited by 303 · see citing works

Repeated Intracerebroventricular Administration of Glucagon-Like Peptide-1-(7–36) Amide or Exendin-(9–39) Alters Body Weight in the Rat**This work was supported by the United Kingdom Medical Research Council.

Meeran, K., O’Shea, D., Edwards, C. M. B., Turton, M. D., Heath, M. M., Gunn, I., Abusnana, S., Rossi, M., Small, C. J., Goldstone, A. P., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6421 · Cited by 303 · see citing works

A Role for β-Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucose-Dependent Insulin Release

Chu, Z., Jones, R. M., He, H., Carroll, C., Gutierrez, V., Lucman, A., Moloney, M. K., Gao, H., Mondala, H., Bagnol, D., et al. (2007) · Endocrinology · doi:10.1210/en.2006-1608 · Cited by 295 · see citing works

Therapeutic Strategies Based on Glucagon-Like Peptide 1

Deacon, C. F. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2181 · Cited by 295 · see citing works

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart

Sonne, D. P., Engstrøm, T., & Treiman, M. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.10.001 · Cited by 294 · see citing works

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM

Nauck, M. A., Wollschläger, D., Werner, J., Holst, J. J., Ørskov, C., Creutzfeldt, W., & Willms, B. (1996) · Diabetologia · doi:10.1007/s001250050613 · Cited by 283 · see citing works

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects

Elbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279 · see citing works

Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans

Schirra, J., Nicolaus, M., Roggel, R., Katschinski, M., Storr, M., Woerle, H. J., & Göke, B. (2005) · Gut · doi:10.1136/gut.2004.059741 · Cited by 275 · see citing works

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

Nikolaidis, L. A., Elahi, D., Shen, Y.-T., & Shannon, R. P. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00347.2005 · Cited by 274 · see citing works

Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy

Parks, M. A., & Rosebraugh, C. J. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1001578 · Cited by 273 · see citing works

Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop.

Roberge, J. N., & Brubaker, P. L. (1993) · Endocrinology · doi:10.1210/endo.133.1.8319572 · Cited by 266 · see citing works

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM

Rachman, J., Barrow, B. A., Lévy, J., & Turner, R. C. (1997) · Diabetologia · doi:10.1007/s001250050664 · Cited by 265 · see citing works

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265 · see citing works

Neonatal Exendin-4 Prevents the Development of Diabetes in the Intrauterine Growth Retarded Rat

Stoffers, D. A., Desai, B. M., León, D. D. D., & Simmons, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.734 · Cited by 261 · see citing works

Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12D Mouse Model

Gier, B., Matveyenko, A. V., Kirakossian, D., Dawson, D., Dry, S. M., & Butler, P. C. (2012) · Diabetes · doi:10.2337/db11-1109 · Cited by 255 · see citing works

Effect of Intravenous Infusion of Exenatide (Synthetic Exendin-4) on Glucose-Dependent Insulin Secretion and Counterregulation During Hypoglycemia

Degn, K., Brock, B., Juhl, C. B., Djurhuus, C., Grubert, J., Kim, D. S., Han, J., Taylor, K., Fineman, M. S., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2397 · Cited by 253 · see citing works

Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

Ristic, S., Byiers, S., Foley, J. E., & Holmes, D. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00539.x · Cited by 248 · see citing works

β-Cell Pdx1 Expression Is Essential for the Glucoregulatory, Proliferative, and Cytoprotective Actions of Glucagon-Like Peptide-1

Li, Y., Cao, X., Li, L., Brubaker, P. L., Edlund, H., & Drucker, D. J. (2005) · Diabetes · doi:10.2337/diabetes.54.2.482 · Cited by 247 · see citing works

Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulation of Pancreatic β-Cell Survival Is Dependent upon Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (PKB) Signaling, Inactivation of the Forkhead Transcription Factor Foxo1, and Down-regulation of bax Expression

Kim, S., Winter, K. D., Nian, C., Tsuneoka, M., Koda, Y., & McIntosh, C. H. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500540200 · Cited by 241 · see citing works

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes

Rosenstock, J., Reusch, J. E. B., Bush, M., Yang, F., Stewart, M. W., & for the Albiglutide Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0366 · Cited by 237 · see citing works

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet

McClean, P. L., Irwin, N., Cassidy, R. S., Holst, J. J., Gault, V. A., & Flatt, P. R. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2007 · Cited by 237 · see citing works

Glucagon-Like Peptide 1 Induces Differentiation of Islet Duodenal Homeobox-1–Positive Pancreatic Ductal Cells Into Insulin-Secreting Cells

Hui, H., Wright, C. V. E., & Perfetti, R. (2001) · Diabetes · doi:10.2337/diabetes.50.4.785 · Cited by 224 · see citing works

American Association of Clinical Endocrinologists’ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.csuppl · Cited by 219 · see citing works

Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate

Kim, J., Baggio, L. L., Bridon, D. P., Castaigne, J., Robitaille, M. F., Jetté, L., Benquet, C., & Drucker, D. J. (2003) · Diabetes · doi:10.2337/diabetes.52.3.751 · Cited by 210 · see citing works

Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons

Vrang, N., Phifer, C. B., Corkern, M. M., & Berthoud, H. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00732.2002 · Cited by 204 · see citing works

GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide

Hegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2010-2318 · Cited by 194 · cited 1× · see citing works

Twelve-week Monotherapy with the DPP-4 Inhibitor Vildagliptin Improves Glycemic Control in Subjects with Type 2 Diabetes

Pratley, R. E., Jauffret, S., Galbreath, E. J., & Holmes, D. (2006) · Hormone and Metabolic Research · doi:10.1055/s-2006-944546 · Cited by 194 · see citing works

Cardiac Function in Mice Lacking the Glucagon-Like Peptide-1 Receptor

Gros, R., You, X., Baggio, L. L., Kabir, M. G., Sadi, A. M., Mungrue, I. N., Parker, T. G., Huang, Q., Drucker, D. J., & Husain, M. (2003) · Endocrinology · doi:10.1210/en.2003-0007 · Cited by 192 · see citing works

On the physiology of GIP and GLP-1

Holst, J. J. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826158 · Cited by 189 · see citing works

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

Nachnani, J. S., Bulchandani, D. G., Nookala, A., Herndon, B., Molteni, A., Pandya, P., Taylor, R., Quinn, T., Weide, L., & Alba, L. M. (2010) · Diabetologia · doi:10.1007/s00125-009-1515-4 · Cited by 189 · see citing works

Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9–39) Amide

Kolligs, F. T., Fehmann, H.-C., Göke, R., & Göke, B. (1995) · Diabetes · doi:10.2337/diab.44.1.16 · Cited by 185 · see citing works

Targeted Ablation of Glucose-dependent Insulinotropic Polypeptide-producing Cells in Transgenic Mice Reduces Obesity and Insulin Resistance Induced by a High Fat Diet

Althage, M. C., Ford, E. L., Wang, S., Tso, P., Polonsky, K. S., & Wice, B. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710466200 · Cited by 180 · see citing works

Chemical Ablation of Gastric Inhibitory Polypeptide Receptor Action by Daily (Pro3)GIP Administration Improves Glucose Tolerance and Ameliorates Insulin Resistance and Abnormalities of Islet Structure in Obesity-Related Diabetes

Gault, V. A., Irwin, N., Green, B. D., McCluskey, J. T., Greer, B., Bailey, C. J., Harriott, P., O'Harte, F. P. M., & Flatt, P. R. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2436 · Cited by 172 · see citing works

A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db / db mice

Chen, D., Liao, J., Li, N., Zhou, C., Liu, Q., Wang, G., Zhang, R., Zhang, S., Lin, L., Chen, K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610173104 · Cited by 171 · see citing works

Pancreatic Duct Glands Are Distinct Ductal Compartments That React to Chronic Injury and Mediate Shh-Induced Metaplasia

Strobel, O., Rosow, D. E., Rakhlin, E. Y., Lauwers, G. Y., Trainor, A. G., Alsina, J., del Castillo, C. F., Warshaw, A. L., & Thayer, S. P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.12.005 · Cited by 162 · see citing works

Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in Mice

Koehler, J. A., Baggio, L. L., Lamont, B. J., Ali, S., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db09-0626 · Cited by 160 · see citing works

Glucose-Dependent Insulinotropic Polypeptide Promotes β-(INS-1) Cell Survival via Cyclic Adenosine Monophosphate-Mediated Caspase-3 Inhibition and Regulation of p38 Mitogen-Activated Protein Kinase

Ehses, J. A., Casilla, V. R., Doty, T., Pospisilik, J. A., Winter, K. D., Demuth, H., Pederson, R. A., & McIntosh, C. H. S. (2003) · Endocrinology · doi:10.1210/en.2002-0068 · Cited by 159 · see citing works

By the numbers: New estimates from the IDF Diabetes Atlas Update for 2012

Guariguata, L. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.11.006 · Cited by 158 · see citing works

Cure of Overt Diabetes in NOD Mice by Transient Treatment With Anti-Lymphocyte Serum and Exendin-4

Ogawa, N., List, J. F., Habener, J. F., & Maki, T. (2004) · Diabetes · doi:10.2337/diabetes.53.7.1700 · Cited by 156 · see citing works

Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM

Dupre, J., Behme, M. T., HRAMIAK, I. M., McFarlane, P. A., Williamson, M. P., Zabel, P. L., & McDonald, T. J. (1995) · Diabetes · doi:10.2337/diab.44.6.626 · Cited by 152 · see citing works

Initiation of Increased Pancreatic Islet Growth in Young Normoglycemic Mice (Umea +/?)*

Edvell, A., & Lindström, P. (1999) · Endocrinology · doi:10.1210/endo.140.2.6514 · Cited by 151 · see citing works

Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat.

Tseng, C., Kieffer, T. J., Jarboe, L. A., Usdin, T. B., & Wolfe, M. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119060 · Cited by 149 · see citing works

The Safety of Incretin-Based Therapies—Review of the Scientific Evidence

Drucker, D. J., Sherman, S. I., Bergenstal, R. M., & Buse, J. B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0599 · Cited by 148 · see citing works

Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs

Deacon, C. F., Danielsen, P. L., Klarskov, L., Olesen, M., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1588 · Cited by 145 · see citing works

Do GLP-1–Based Therapies Increase Cancer Risk?

Nauck, M. A., & Friedrich, N. (2013) · Diabetes Care · doi:10.2337/dcs13-2004 · Cited by 145 · see citing works

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

Engel, S. S., Williams‐Herman, D., Golm, G. T., Clay, R. J., Machotka, S. V., Kaufman, K. D., & Goldstein, B. J. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02382.x · Cited by 143 · see citing works

Glucagon-Like Peptide-1 Regulates the Beta Cell Transcription Factor, PDX-1, in Insulinoma Cells

Wang, X., Cahill, C. M., Piñeyro, M. A., Zhou, J., Doyle, M. E., & Egan, J. M. (1999) · Endocrinology · doi:10.1210/endo.140.10.7158 · Cited by 139 · see citing works

Vaccination against GIP for the Treatment of Obesity

Fulurija, A., Lutz, T. A., Sladko, K., Osto, M., Wielinga, P. Y., Bachmann, M. F., & Saudan, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003163 · Cited by 136 · see citing works

Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients.

Phillips, W. T., Schwartz, J. G., & McMahan, C. A. (1992) · PubMed · Cited by 135 · see citing works

Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential

Holst, J. J. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(99)00157-5 · Cited by 131 · see citing works

Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat

Piteau, S., Olver, A., Kim, S.-J., Winter, K., Pospisilik, J. A., Lynn, F., Manhart, S., Demuth, H.-U., Speck, M., Pederson, R. A., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.115 · Cited by 130 · see citing works

The Human GLP-1 Analog Liraglutide and the Pancreas

Nyborg, N. C. B., Mølck, A.-M., Madsen, L. W., & Bjerre Knudsen, L. (2012) · Diabetes · doi:10.2337/db11-0936 · Cited by 125 · see citing works

Prohormone Convertase 1/3 Is Essential for Processing of the Glucose-dependent Insulinotropic Polypeptide Precursor

Ugleholdt, R., Poulsen, M.-L. H., Holst, P. J., Irminger, J.-C., Ørskov, C., Pedersen, J., ROSENKILDE, M. M., Zhu, X., Steiner, D. F., & Holst, J. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601203200 · Cited by 124 · see citing works

Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes

Azuma, K., Rádiková, Ž., Mancino, J., Toledo, F. G. S., Thomas, E., Kangani, C. O., Man, C. D., Cobelli, C., Holst, J. J., Deacon, C. F., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1369 · Cited by 121 · see citing works

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.

D’Alessio, D. A., Vogel, R., Prigeon, R. L., Laschansky, E. C., Koerker, D. J., Eng, J., & Ensinck, J. W. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118380 · Cited by 118 · see citing works

Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes

Deacon, C. F., & Holst, J. J. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.09.011 · Cited by 117 · see citing works

Impaired Intestinal Proglucagon Processing in Mice Lacking Prohormone Convertase 1

Ugleholdt, R., Zhu, X., Deacon, C. F., Ørskov, C., Steiner, D. F., & Holst, J. J. (2003) · Endocrinology · doi:10.1210/en.2003-0801 · Cited by 115 · see citing works

Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling.

Scrocchi, L. A., Marshall, B. A., Cook, S., Brubaker, P. L., & Drucker, D. J. (1998) · Diabetes · doi:10.2337/diabetes.47.4.632 · Cited by 114 · see citing works

Global Prevalence and Future of Diabetes Mellitus

GINTER, E., & Simko, V. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_5 · Cited by 110 · see citing works

Improved Glucose Tolerance via Enhanced Glucose-Dependent Insulin Secretion in Dipeptidyl Peptidase IV-Deficient Fischer Rats

Nagakura, T., Yasuda, N., Yamazaki, K., Ikuta, H., Yoshikawa, S., Asano, O., & Tanaka, I. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4999 · Cited by 96 · see citing works

Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice

Scrocchi, L. A., & Drucker, D. J. (1998) · Endocrinology · doi:10.1210/endo.139.7.6092 · Cited by 95 · see citing works

Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations

Ahr�n, B., & Larsson, H. (2001) · Diabetologia · doi:10.1007/s001250100003 · Cited by 95 · see citing works

Exendin‐4 differentiation of a human pancreatic duct cell line into endocrine cells: Involvement of PDX‐1 and HNF3β transcription factors

Zhou, J., Piñeyro, M. A., Wang, X., Doyle, M. E., & Egan, J. M. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10143 · Cited by 95 · see citing works

Association of Pancreatitis with Glucagon-Like Peptide-1 Agonist Use

Anderson, S. L., & Trujillo, J. M. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m676 · Cited by 95 · see citing works

A randomized, open-label, crossover study examiningthe effect of injection site on bioavailability of exenatide (synthetic exendin-4)

Calara, F. B., Taylor, K., Han, J., Zabala, E., Carr, E. M., Wintle, M. E., & Fineman, M. S. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.02.008 · Cited by 94 · see citing works

The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with Type 2 (non-insulin-dependent) diabetes mellitus

Jones, I. R., Owens, D. R., Luzio, S. D., Williams, S. E. I., & Hayes, T. M. (1989) · Diabetologia · doi:10.1007/bf00274255 · Cited by 91 · see citing works

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents

Tatarkiewicz, K., Smith, P. A., Sablan, E. J., Polizzi, C. J., Aumann, D. E., Villescaz, C., Hargrove, D. M., Gedulin, B. R., Lu, M. G. W., Adams, L., et al. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00479.2010 · Cited by 91 · see citing works

Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop

Roberge, J. N. (1993) · Endocrinology · doi:10.1210/en.133.1.233 · Cited by 88 · see citing works

Activation of the GLP-1 Receptor Signalling Pathway: A Relevant Strategy to Repair a Deficient Beta-Cell Mass

Portha, B., Tourrel-Cuzin, C., & Movassat, J. (2011) · Experimental Diabetes Research · doi:10.1155/2011/376509 · Cited by 85 · see citing works

GLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions

Gutniak, M., Larsson, H., Sanders, S. W., Juneskans, O. T., Holst, J. J., & Åhrén, B. (1997) · Diabetes Care · doi:10.2337/diacare.20.12.1874 · Cited by 84 · see citing works

GLP1-derived nonapeptide GLP1(28–36)amide protects pancreatic β-cells from glucolipotoxicity

Liu, Z., Stanojevic, V., Brindamour, L. J., & Habener, J. F. (2012) · Journal of Endocrinology · doi:10.1530/joe-11-0328 · Cited by 83 · see citing works

Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy

Waser, B., Beetschen, K., Pellegata, N. S., & Reubi, J. C. (2011) · Neuroendocrinology · doi:10.1159/000330447 · Cited by 80 · see citing works

Glucagon-Like Peptide-1, But Not Glucose-Dependent Insulinotropic Peptide, Regulates Fasting Glycemia and Nonenteral Glucose Clearance in Mice

Baggio, L. L., Kieffer, T. J., & Drucker, D. J. (2000) · Endocrinology · doi:10.1210/endo.141.10.7720 · Cited by 79 · see citing works

Suppression of Pdx-1 perturbs proinsulin processing, insulin secretion and GLP-1 signalling in INS-1 cells

Wang, H., Iezzi, M., Theander, S. S., Antinozzi, P. A., Gauthier, B. R., Halban, P. A., & Wollheim, C. B. (2005) · Diabetologia · doi:10.1007/s00125-005-1692-8 · Cited by 79 · see citing works

Dose–response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats

Gedulin, B. R., Smith, P., Prickett, K. S., Tryon, M. S., Barnhill, S. D., Reynolds, J., Nielsen, L. L., Parkes, D. G., & Young, A. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1795-2 · Cited by 77 · see citing works

Update of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2011

(2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.02.005 · Cited by 75 · see citing works

GLP-1–Based Therapy for Diabetes: What You Do Not Know Can Hurt You

Butler, P. C., Dry, S., & Elashoff, R. M. (2010) · Diabetes Care · doi:10.2337/dc09-1902 · Cited by 69 · see citing works

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction

Russell, S. (2012) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-012-9729-9 · Cited by 66 · see citing works

Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives

Ahrén, B. (2013) · Diabetes &amp; Metabolism · doi:10.1016/j.diabet.2013.03.001 · Cited by 64 · see citing works

Clinical utility of insulin and insulin analogs

Şanlioğlu, A. D., Altunbaş, H., Balcı, M. K., Griffith, T. S., & Şanlıoğlu, S. (2013) · Islets · doi:10.4161/isl.24590 · Cited by 64 · see citing works

A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer

Chiu, W.-Y., Shih, S.-R., & Tseng, C.-H. (2012) · Experimental Diabetes Research · doi:10.1155/2012/924168 · Cited by 63 · see citing works

Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials

Gurney, K., MacConell, L., Brown, C. J., & Han, J. (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s28387 · Cited by 61 · see citing works

Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogs of JANUVIA™ (sitagliptin phosphate)

Kim, D., Kowalchick, J. E., Edmondson, S. D., Mastracchio, A., Xu, J., Eiermann, G. J., Leiting, B., Wu, J. K., Pryor, K. D., Patel, R. A., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.03.098 · Cited by 58 · see citing works

Acute Pancreatitis Associated with Liraglutide

Lee, P. H., Stockton, M. D., & Franks, A. S. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p714 · Cited by 57 · see citing works

Impairment of GLP1 ‐induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia

Herzberg-Schäfer, S. A., Heni, M., Stefan, N., Häring, H., & Fritsche, A. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01648.x · Cited by 56 · see citing works

No evidence of drug‐induced pancreatitis in rats treated with exenatide for 13 weeks

Tatarkiewicz, K., Belanger, P., Gu, G., Parkes, D., & Roy, D. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12040 · Cited by 56 · see citing works

GPR119: “Double-Dipping” for Better Glycemic Control

Lauffer, L., Iakoubov, R., & Brubaker, P. L. (2008) · Endocrinology · doi:10.1210/en.2008-0182 · Cited by 55 · see citing works

Release of gastric inhibitory polypeptide from cultured canine endocrine cells

Kieffer, T. J., Buchan, A. M. J., Barker, H., et al. (1994) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1994.267.4.e489 · Cited by 50 · see citing works

Boc5, a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist, Invokes Sustained Glycemic Control and Weight Loss in Diabetic Mice

Su, H., He, M., Li, H., Liu, Q., Wang, J., Wang, Y., Gao, W., Zhou, L., Liao, J., Young, A. A., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002892 · Cited by 49 · see citing works

Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice

Irwin, N., Gault, V. A., Green, B. D., Greer, B., McCluskey, J. T., Harriott, P., O'Harte, F. P. M., & Flatt, P. R. (2004) · Biological Chemistry · doi:10.1515/bc.2004.110 · Cited by 49 · see citing works

Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db / db mice

Joseph, J. W., Kalitsky, J., St-Pierre, S. A., & Brubaker, P. L. (2000) · Diabetologia · doi:10.1007/s001250051529 · Cited by 48 · see citing works

Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: A Proof-of-concept Study in Healthy Subjects

Beglinger, C., Poller, B., Arbit, E., Ganzoni, C., Gass, S., Gómez-Orellana, I., & Drewe, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.35 · Cited by 48 · see citing works

Managed Care Perspective on Three New Agents for Type 2 Diabetes

VanDeKoppel, S., Choe, H. M., & Sweet, B. V. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.4.363 · Cited by 44 · see citing works

Initiation of Increased Pancreatic Islet Growth in Young Normoglycemic Mice (Umea +/?)

Edvell, A. (1999) · Endocrinology · doi:10.1210/en.140.2.778 · Cited by 44 · see citing works

Therapeutic potential of VIP vs PACAP in diabetes

Şanlioğlu, A. D., Karaçay, B., Balcı, M. K., Griffith, T. S., & Şanlıoğlu, S. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0156 · Cited by 43 · see citing works

Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo

Green, B., Gault, V. A., Mooney, M., Irwin, N., Bailey, C. J., Harriott, P., Greer, B., Flatt, P. R., & O'Harte, F. P. M. (2003) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0310529 · Cited by 36 · see citing works

Pancreatitis: A Potential Complication of Liraglutide?

Franks, A. S., Lee, P. H., & George, C. M. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q789 · Cited by 34 · see citing works

GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1

Li, Y., Zheng, X., Tang, L., Xu, W., & Gong, M. (2011) · Peptides · doi:10.1016/j.peptides.2011.04.001 · Cited by 33 · see citing works

GLP-1–Based Therapies and the Exocrine Pancreas: More Light, or Just More Heat?

Gale, E. A. (2012) · Diabetes · doi:10.2337/db11-1838 · Cited by 32 · see citing works

Collateral damage: the conundrum of drug safety

Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1491-8 · Cited by 31 · see citing works

Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117

Qian, F., Mathias, N. R., Moench, P. A., et al. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.10.020 · Cited by 30 · see citing works

Clinical Implications of Exenatide as a Twice-Daily or Once-Weekly Therapy for Type 2 Diabetes

Aroda, V. R., & DeYoung, M. B. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.09.2479 · Cited by 27 · see citing works

AACE Comprehensive Diabetes Management Algorithm 2013 Endocrine Practice

Tamez-Pérez, H. E., Proskauer-Peña, S. L., & Hernández-Coria, M. I. (2013) · Endocrine Practice · doi:10.4158/ep13210.lt · Cited by 21 · see citing works

Insulin gene therapy from design to beta cell generation

Şanlioğlu, A. D., Altunbaş, H., Balcı, M. K., Griffith, T. S., & Şanlıoğlu, S. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.12 · Cited by 16 · see citing works

Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus

Ryan, G. J., Moniri, N. H., & Smiley, D. D. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120168 · Cited by 16 · see citing works

Comment on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 2013;62:2595–2604

Engel, S. S., Golm, G. T., & Lauring, B. P. (2013) · Diabetes · doi:10.2337/db13-0525 · Cited by 15 · see citing works

GLP-1 Receptor Agonist Effects on Normal and Neoplastic Pancreata

Goggins, M. (2012) · Diabetes · doi:10.2337/db12-0233 · Cited by 13 · see citing works

Comment on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 2013;62:2595–2604

Heine, R. J., Fu, H., Kendall, D. M., & Moller, D. E. (2013) · Diabetes · doi:10.2337/db13-0690 · Cited by 12 · see citing works

Prediabetes diagnosis and treatment: A review

Bansal, N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i2.296 · Cited by 579 · see citing works

Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments

Wang, M., Tan, Y., Shi, Y., Wang, X., Liao, Z., & Wei, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00568 · Cited by 231 · see citing works

Semaglutide: review and place in therapy for adults with type 2 diabetes

Goldenberg, R. M., & Steen, O. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.05.008 · Cited by 91 · see citing works

Diabetes after Bariatric Surgery

Shah, A., & Laferrère, B. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.12.009 · Cited by 50 · see citing works

Bidirectional Relationship between Gastric Emptying and Plasma Glucose Control in Normoglycemic Individuals and Diabetic Patients

Mihai, B. M., Mihai, C., Cijevschi-Prelipcean, C., Grigorescu, E.-D., Dranga, M., Drug, V., Sporea, I., & Lăcătușu, C. M. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1736959 · Cited by 46 · see citing works

Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review

Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38 · see citing works

Are the Changes in Gastrointestinal Hormone Secretion Necessary for the Success of Bariatric Surgery? A Critical Review of the Literature

Lampropoulos, C., Alexandrides, T., Tsochatzis, S., Kehagias, D., & Kehagias, I. (2021) · Obesity Surgery · doi:10.1007/s11695-021-05568-7 · Cited by 30 · see citing works

Evaluation of the risk of fracture in type 2 diabetes mellitus patients with incretins: an updated meta-analysis

Kong, Q.-X., Ruan, Q., Fan, C., Liu, B.-L., Reng, L.-P., & Xu, W. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0031 · Cited by 22 · see citing works

Lixisenatida en pacientes con diabetes tipo 2 y obesidad: más allá del control glucémico

Roca-Rodríguez, M. M., Muros de Fuentes, M. T., Piédrola-Maroto, G., Quesada-Charneco, M., Maraver-Selfa, S., Tinahones, F. J., & Mancha-Doblas, I. (2017) · Atención Primaria · doi:10.1016/j.aprim.2016.06.009 · Cited by 8 · see citing works

The role of incretin-based therapies in the management of type 2 diabetes

Bandyopadhyay, P. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.9.1434633 · Cited by 2 · see citing works

Incretin-based therapies for type 2 diabetes

Capaldi, B. (2012) · Practice Nursing · doi:10.12968/pnur.2012.23.10.508

No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect

Mathiesen, D. S., Bagger, J. I., Hansen, K. B., Junker, A. E., Plamboeck, A., Østoft, S. H., Idorn, T., Hornum, M., Holst, J. J., Jonsson, A. E., et al. (2020) · Endocrine Connections · doi:10.1530/ec-20-0471 · Cited by 5 · see citing works

Incretin therapies for type 2 diabetes: what nurses need to know

Capaldi, B. (2012) · Nurse Prescribing · doi:10.12968/npre.2012.10.7.345

Glucagon-like peptide-1 (GLP-1): a piece of the incretin puzzle.

Weir, G. C. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117625 · Cited by 14 · see citing works